Inventor
David Baltimore
Inventor
Pasadena, CA, US
Overview
Patents· 73 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C12Nprimary
C12NMicroorganisms or enzymes23%
A61KPreparations for medical, dental or toiletry purposes20%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations16%
C07KPeptides14%
Y02ATechnologies for adaptation to climate change13%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms6%
G01NInvestigating or analysing materials by determining their chemical or physical properties5%
A01KAnimal husbandry2%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%
C07HSugars0%
PatentTitleYear
11,125,755Ligand discovery for T cell receptors202111,125,756Ligand discovery for T cell receptors202110,876,118Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell202010,876,133Method for expression of small RNA molecules within a cell202010,816,554Ligand discovery for T cell receptors202010,739,351Functional characterization of immune repertoires202010,696,984Packaging cell for making a pseudotyped lentivirus202010,435,689MicroRNA inhibition for the treatment of inflammation and myeloproliferative disorders201910,266,847Methods of delivering a pseudotyped lentivirus201910,041,072Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell201810,006,053Use of chimeric nucleases to stimulate gene targeting20189,994,867Method of targeting gene delivery using viral vectors20189,963,717Method for expression of small RNA molecules within a cell20189,943,611Reversible gene expression20189,884,075'Domain-swap T cell receptors'20189,862,948'Microrna inhibition for the treatment of inflammation and myeloproliferative disorders'20189,840,721'Recombinant retrovirus pseudotyped with E2 alphavirus glycoprotein'20179,696,296'Targeting c-Rel O-GlcNAcylation and uses thereof'20179,567,592'Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell'20179,551,011'Method for expression of small RNA molecules within a cell'20179,540,657'Expression of secreted and cell-surface polypeptides'20179,527,904'Delivery of proteins using adeno-associated virus (AAV) vectors'20169,447,434'Use of chimeric nucleases to stimulate gene targeting'20169,303,072'Method of stimulating an immune response using a pseudotyped lentivirus'20169,290,761'MicroRNA inhibition for the treatment of inflammation and myeloproliferative disorders'20169,267,140'Method for producing transgenic animals'20169,145,560'Method for producing transgenic rats'20159,090,894'Modulating immune system development and function through microRNA MIR-146'20159,034,577'Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell'20159,006,195'Regulation of hematopoietic stem cell functions through microRNAs'20158,969,076'Method for expression of small RNA molecules within a cell'20158,906,359'Recombinant retrovirus pseudotyped with a E2 alphavirus glycoprotein'20148,865,881'Delivery of proteins using adeno-associated virus (AAV) vectors'20148,821,856'Method of targeted gene delivery using viral vectors'20148,715,640'Packaging cells for producing retrovirus pseudotyped with an E2 alphavirus glycoprotein'20148,697,672'Microrna inhibition for the treatment of inflammation and myeloproliferative disorders'20148,685,727'Regulation of macrophage activation using miR-125b'20148,669,235'Modulation of innate immunity receptors\' signaling by microRNAs miR-146a and miR-146b'20148,598,137'Use of SAM68 for modulating signaling through the TNF receptor'20138,552,150'MART-1 T cell receptors'20138,497,071'Isolation of unknown rearranged T-cell receptors from single cells'20138,372,390'Recombiant lentivirus comprising an E2 alphavirus glycoprotein that binds to DC-SIGN'20138,361,982'Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell'20138,361,787'Method for expression of small RNA molecules within a cell'20138,329,162'Targeted gene delivery for dendritic cell vaccination'20128,313,643'System and method for analyzing a biological sample'20128,273,345'Targeted gene delivery to dendritic cells'20128,133,727'In vitro human B lymphopoiesis culture system'20128,119,772'MART-1 T cell receptors'20127,939,059'Method for the generation of antigen-specific lymphocytes'20117,919,309'Method for expression of small antiviral RNA molecules within a cell'20117,737,124'Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell'20107,732,193'Method for expression of small RNA molecules within a cell'20107,732,207'Method for expression of small antiviral RNA molecules within a cell'20107,323,619'Method for producing transgenic birds and fish'20087,195,916'Method for expression of small antiviral RNA molecules within a cell'20076,994,967'Transcription factor regulators and methods for screening for same'20066,916,917'Chimeric pro-caspases and methods of using same'20056,822,070'Truncated CRAF1 inhibits CD40 signaling'20046,410,516'Nuclear factors associated with transcriptional regulation'20026,159,731'Daxx, a Fas-binding protein that activates JNK and apoptosis'20006,150,090'Nuclear factors associated with transcriptional regulation'20006,146,614'Method for determining lymphocyte distribution and trafficking in mammals using imaging'20005,919,458'Non-infectious HIV particles and uses therefor'19995,861,282'Non-infectious HIV particles and uses therefor'19995,804,374'Nuclear factors associates with transcriptional regulation'19985,674,680'Methods for the prognosis and monitoring of AIDS'19975,516,630'Methods of detecting hepatitis A virus'19965,358,856'Gene expression in mammalian cells using a cap independent 5\' noncoding region'19945,230,888'Production of neutralizing antibodies by polypeptide VP1 of enteroviruses and by oligopeptide fragments of polypeptide VP1'19935,159,066'Recombination activating gene (RAG-1)'19924,751,083'Production of neutralizing antibodies by polypeptide VP1 of enteroviruses and by oligopeptide fragments of polypeptide VP1'19884,719,177'Production of complementary DNA representing RNA viral sequences by recombinant DNA methods and uses therefor'1988Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1988–2002Patents assigned to MASSACHUSETTS INST TECHNOLOGY (7)· patent assignee history
1988–1993Based in Cambridge, MA, US· patent location history
1994–2002Based in New York, NY, US· patent location history
2000–2021Based in Pasadena, CA, US· patent location history
2004Based in Boston, MA, US· patent location history
2005–2021Patents assigned to CALIFORNIA INST OF TECHN (57)· patent assignee history
2007–2020Patents assigned to UNIV CALIFORNIA (8)· patent assignee history
2012–2016Patents assigned to BALTIMORE DAVID (22)· patent assignee history
2012–2014Patents assigned to WANG PIN (7)· patent assignee history
2012Based in Newtown, CT, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| CALIFORNIA INST OF TECHN | 57 | 2005–2021 |
| BALTIMORE DAVIDself | 22 | 2012–2016 |
| UNIV CALIFORNIA | 8 | 2007–2020 |
| MASSACHUSETTS INST TECHNOLOGY | 7 | 1988–2002 |
| WANG PIN | 7 | 2012–2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| Pasadena, California, US | 59 | 2000–2021 |
| New York, New York, US | 8 | 1994–2002 |
| Cambridge, Massachusetts, US | 4 | 1988–1993 |
| Newtown, CT, US | 1 | 2012 |
| Boston, Massachusetts, US | 1 | 2004 |